AHCC (Active Hexose Correlated Compound) and cancer care
What 3 graded rows on ahcc (active hexose correlated compound) agree on for cancer care, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the AHCC (Active Hexose Correlated Compound) page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the AHCC (Active Hexose Correlated Compound) page, with its PubMed record.
Your question
AHCC (Active Hexose Correlated Compound) and cancer care
3 rows · 202 peopleSplit. 1 row found an improvement and 2 had mixed results.
- CGrade C× 1
- DGrade D× 2
- Rows
- 3
- Trials
- 3
- People
- 202
What the rows share
From the rowsThe best-graded row, grade C, is a randomized trial of 98 people (2023) and reported mixed results.
The rows run from 29 to 98 people, published from 2016 to 2023: 3 single studies.
The rows
1 improved · 2 mixed- DGrade DChemotherapy side effects in pancreatic cancer (non-randomised) · Improved
Open-label trial · n 75 · 2016 · 75 patients with unresectable pancreatic cancer starting gemcitabine in Japan (35 AHCC, 40 no AHCC), not randomised
6.0 g a day · 2 months
Taste disorder was less frequent with AHCC (17% vs 56%, P = 0.0007); CRP rise and albumin fall were smaller, and grade 3 of the modified Glasgow Prognostic Score was less frequent (14% vs 53%).
Row on the AHCC (Active Hexose Correlated Compound) page · PubMed 26847832 (opens PubMed)
- CGrade CTaste disorders and anaemia during chemotherapy · Mixed
RCT · n 98 · 2023 · 98 patients with pancreatic cancer on chemotherapy in Japan (55 AHCC, 43 placebo)
Dose not stated in the abstract · During chemotherapy
Taste disorders were less frequent with AHCC (risk difference 28.6%, 95% CI 7.5% to 47.8%) and nutrition markers improved; grade 2-3 anaemia did not differ (-3.1%).
Row on the AHCC (Active Hexose Correlated Compound) page · PubMed 35950537 (opens PubMed)
- DGrade DLiver cancer recurrence after surgery (single arm) · Mixed
Open-label trial · n 29 · 2022 · 29 patients after curative surgery for hepatocellular carcinoma (BCLC stage A or B); 25 followed without stopping
1 g three times a day (3 g a day) · 2 years
2-year recurrence-free survival was 48% in those who did not stop and 55.2% in all treated; no toxicity or adverse events were seen. With no control group, the effect on recurrence cannot be judged.
Row on the AHCC (Active Hexose Correlated Compound) page · PubMed 35075934 (opens PubMed)